Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update for pembrolizumab plus chemotherapy versus placebo plus chemotherapy in HR+/HER2- locally recurrent inoperable or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING